Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer

May 14, 2019

DURHAM, N.C., May 14, 2019 (GLOBE NEWSWIRE) — Precision BioSciences (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, announced today that Christopher R. Heery, M.D. has joined Precision BioSciences as its Chief Medical Officer.

“We are thrilled to welcome Chris Heery as our Chief Medical Officer. Chris has exceptional experience in the rapidly evolving field of cell therapies and has led many first-in-human clinical trials during his time at the National Cancer Institute (NCI). We believe his skill set and experience are a perfect fit to guide our off-the-shelf immunotherapy and in vivo gene correction programs through human clinical trials,” said Matt Kane, Chief Executive Officer and co-founder of Precision BioSciences.

Full press release here.